Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Glad to see the breakout on the chart yesterday. LTT!
Great times ahead for the months/years to come.
ICE
Agree. The only penny I’m holding at the moment. Still very early here. The story is just starting.
kt
Finally ready to leave the nest and spread its wings.
$MRES, if anyone has done their Due Diligence here, they know this is worth .10+ and that's conservative and no hype whatsoever. https://t.co/hFCc8AMcco
— learningthetruth (@learningdatruth) March 14, 2024
DTC shares only 135 mil. Tiny for OTC. Seller gone , level 2 is thin and Hempcelium division spinoff coming.
31. March is near. Be sure you have your tickets . M2MMA Phuket
Fantastic... thanks for posting this information.
Starting to trade a little better lately.
I saw that too yesterday. Weird
What’s with the 670 something shares traded like 25% above the ask price this morning?
Agreed. I keep grabbing them while their cheap. 💪🏻
Just a matter of time before folks realize this is incredibly undervalued. I’m surprised the share price is so low.
hmm.. what's happening here? She's rumbling a bit.
Also good to see who ever is selling someone is buying it up I think that’s a good sign of accumulation for somebody
Good to see this moving again I think this giant is starting to wake up from the winter hibernation lol glta
Website is very powerful. Excellent
M2MMA website has been updated and looks amazing! This trades under RLAB and is majority owned by MRES. With the first M2MMA events about to launch this month, these will bring a lot more eyes onto both RLAB and MRES imo..
https://m2mma.com/
I sure hope so
Somebody knows we goin UP !$! MRES
Somebody wanted more MRES near the end of today....
MRES
ICE
Well I believe the MRES share count may be lowered even more , like soon
Makes that calculation for MRES even more valuable
Instead of 60, might be closer to 30
MRES: M2Bio Sciences Provides Corporate Update
NEWS PROVIDED BY
M2Bio Sciences Food and Beverage (Pty) Ltd
March 01, 2024, 13:29 GMT
Institute of Biomedical Research Corp. (OTCBB:MRES)
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, March 1, 2024 /EINPresswire.com/ -- Institute of Biomedical Research Corporation (OTC PINK: MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK: RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).
The transaction was completed and finalized through a complete share-based settlement, leading to a change in control of Real American Capital Corporation. If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
It has been previously disclosed that MRES's CEO, Jeff Robinson, and CFO, Willem Jonker, have been appointed as the Chairman and Chief Financial Officer of RLAB, respectively.
The MRES organogram:
MRES has several divisions that may, after incubation within MRES, be spun out into their own publicly traded entities:
M2Bio Food and Beverage owns and operates three consumer goods brands: Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span many premium CBD-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa, the company and its brands are positioned in the high-value market segment. To cement its status within this premium market segment, M2Bio is committed to an unwavering standard of excellence, prioritizing procuring and producing superior-quality components. This includes using pharmaceutical-grade CBD extracts, premium-grade coffees, and the finest extra virgin olive oils, ensuring consistent delivery of unparalleled product quality and consumer experience.
In March 2023, the Company signed a distribution agreement with Innovative Holdings Alliance Inc. to distribute the Company’s products in the United States of America. The Company’s products are well suited to the premium markets in the USA.
Furthermore, MRES has established a landmark collaboration with the University of Pretoria and Enterprises University of Pretoria to inaugurate the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research. This initiative is dedicated to AI-driven phytomedicine research, propelling MRES's ongoing investigations into plant-based medicines and leveraging Artificial Intelligence and Machine Learning in drug discovery and forensic science.
The Centre is set to revolutionize the field with its extensive database of over 15,000 endemic African plants, offering a rich resource for AI applications in pharmaceutical research. In an innovative approach, the Centre will also integrate NFTs and digital tokens to make the drug discovery process more accessible and democratic.
M2Biome encompasses the nutritional and educational facets of M2Bio Sciences, focusing on the critical connection between gut health and overall wellness. A growing body of evidence highlights the importance of nurturing the microbiome through lifestyle choices. M2Biome is dedicated to delivering products grounded in scientific research tailored to meet the diverse needs of individuals while maintaining the highest standards of quality and environmental sustainability. Our commitment lies in relentless innovation, aiming to offer advanced solutions for enhanced well-being.
M2Enviro, a leader in biotechnological innovation and environmental stewardship, spearheads advancements in mycelium technology to develop innovative, sustainable products. This division is committed to transforming material science by providing eco-conscious alternatives to conventional, harmful petroleum-based materials prevalent today. In 2023, our efforts led to significant achievements in research and development, resulting in the launch of our pioneering product, Hempcelium™.
M2Sentient delves into the interplay between the human sensory system and mental health. In the realm of human biology, the sensory modalities—visual (sight), auditory (hearing), tactile (touch), gustatory (taste), and olfactory (smell)—serve as the primary interfaces between the external environment and our internal psychological landscape. These sensory channels are not merely conduits for data; they are integral to our cognitive processing, shaping our perception, emotion, and cognition.
In the psychological context, Sentience denotes the capacity for conscious perception and experience. It embodies the ability to undergo subjective experiences, encompassing awareness and responsiveness to the environment. This concept is a cornerstone of human consciousness, deeply intertwined with sensory input and interpretation.
The exploration of sentience and the sensory mechanisms offers a nuanced understanding of their pivotal roles in shaping human behavior and mental health. By investigating how sensory experiences influence psychological states, M2 Sentient aims to unravel the complex dynamics of human consciousness and develop innovative approaches to mental health treatment, emphasizing the profound connection between our sensory experiences and overall psychological well-being.
M2Bio Kids represents the nascent division within MRES, spearheading an innovative endeavor to optimize mental and physical health during the critical developmental period from infancy through early childhood (up to five years of age). Anchored in the advanced confluence of biotechnological research and pediatric health sciences, M2Bio Kids is positioned to transform early childhood development strategies. This initiative adopts an integrative methodology, focusing on dietary and nutritional interventions, physical activities, cognitive exercises, and enhancing critical thinking skills through AI-driven hardware and software applications. This comprehensive approach fosters holistic growth and development in the early years, setting a foundation for lifelong health and well-being.
Real American Capital Corporation (OTC PINK: RLAB) is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "RLAB." https://www.otcmarkets.com/stock/RLAB/.
Contact:
Jeff Robinson, CEO
Jeff@m2bio.co
+27 72 333 2148
MRES: M2Bio Sciences Provides Corporate Update
Friday, 01 March 2024 09:10 AM
ACCESSWIRE | Article Logo
Institute of BioMedical Research Corp.
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK:RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).
The transaction was completed and finalized through a complete share-based settlement, leading to a change in control of Real American Capital Corporation. If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
It has been previously disclosed that MRES's CEO, Jeff Robinson, and CFO, Willem Jonker, have been appointed as the Chairman and Chief Financial Officer of RLAB, respectively.
The MRES organogram
MRES has several divisions that may, after incubation within MRES, be spun out into their own publicly traded entities:
M2Bio Food and Beverage owns and operates three consumer goods brands: Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span many premium CBD-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa, the company and its brands are positioned in the high-value market segment. To cement its status within this premium market segment, M2Bio is committed to an unwavering standard of excellence, prioritizing procuring and producing superior-quality components. This includes using pharmaceutical-grade CBD extracts, premium-grade coffees, and the finest extra virgin olive oils, ensuring consistent delivery of unparalleled product quality and consumer experience.
In March 2023, the Company signed a distribution agreement with Innovative Holdings Alliance Inc. to distribute the Company's products in the United States of America. The Company's products are well suited to the premium markets in the USA.
Furthermore, MRES has established a landmark collaboration with the University of Pretoria and Enterprises University of Pretoria to inaugurate the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research. This initiative is dedicated to AI-driven phytomedicine research, propelling MRES's ongoing investigations into plant-based medicines and leveraging Artificial Intelligence and Machine Learning in drug discovery and forensic science.
The Centre is set to revolutionize the field with its extensive database of over 15,000 endemic African plants, offering a rich resource for AI applications in pharmaceutical research. In an innovative approach, the Centre will also integrate NFTs and digital tokens to make the drug discovery process more accessible and democratic.
M2Biome encompasses the nutritional and educational facets of M2Bio Sciences, focusing on the critical connection between gut health and overall wellness. A growing body of evidence highlights the importance of nurturing the microbiome through lifestyle choices. M2Biome is dedicated to delivering products grounded in scientific research tailored to meet the diverse needs of individuals while maintaining the highest standards of quality and environmental sustainability. Our commitment lies in relentless innovation, aiming to offer advanced solutions for enhanced well-being.
M2Enviro, a leader in biotechnological innovation and environmental stewardship, spearheads advancements in mycelium technology to develop innovative, sustainable products. This division is committed to transforming material science by providing eco-conscious alternatives to conventional, harmful petroleum-based materials prevalent today. In 2023, our efforts led to significant achievements in research and development, resulting in the launch of our pioneering product, Hempcelium™.
M2Sentient delves into the interplay between the human sensory system and mental health. In the realm of human biology, the sensory modalities-visual (sight), auditory (hearing), tactile (touch), gustatory (taste), and olfactory (smell)-serve as the primary interfaces between the external environment and our internal psychological landscape. These sensory channels are not merely conduits for data; they are integral to our cognitive processing, shaping our perception, emotion, and cognition.
In the psychological context, Sentience denotes the capacity for conscious perception and experience. It embodies the ability to undergo subjective experiences, encompassing awareness and responsiveness to the environment. This concept is a cornerstone of human consciousness, deeply intertwined with sensory input and interpretation.
The exploration of sentience and the sensory mechanisms offers a nuanced understanding of their pivotal roles in shaping human behavior and mental health. By investigating how sensory experiences influence psychological states, M2 Sentient aims to unravel the complex dynamics of human consciousness and develop innovative approaches to mental health treatment, emphasizing the profound connection between our sensory experiences and overall psychological well-being.
M2Bio Kids represents the nascent division within MRES, spearheading an innovative endeavor to optimize mental and physical health during the critical developmental period from infancy through early childhood (up to five years of age). Anchored in the advanced confluence of biotechnological research and pediatric health sciences, M2Bio Kids is positioned to transform early childhood development strategies. This initiative adopts an integrative methodology, focusing on dietary and nutritional interventions, physical activities, cognitive exercises, and enhancing critical thinking skills through AI-driven hardware and software applications. This comprehensive approach fosters holistic growth and development in the early years, setting a foundation for lifelong health and well-being.
Real American Capital Corporation (OTC PINK:RLAB) is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "RLAB." https://www.otcmarkets.com/stock/RLAB/.
Contact:
Jeff Robinson, CEO
Jeff@m2bio.co
+27 72 333 2148
Wish they would have spelled it out a little better and given a date. Guess we'll see??
kt
I think this is the link you wanted to post:
https://www.accesswire.com/838150/mres-m2bio-sciences-provides-corporate-update
If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
So MRES holders would have around 40m shares of RLAB. So about 1 share for every 60 shares of MRES? That's just based on OS of 2,371,424,113 divided by 40 million is around 60.
Just off the top of my head......buying 100k of MRES here at .0085($850) gets you 1,666 shares of RLAB trading at .20($333).
kt
News: RLAB and MRES : If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
https://www.einpresswire.com/article/692582141/mres-m2bio-sciences-provides-corporate-update
https://www.accesswire.com/836151/mres-m2bio-sciences-introduces-m2biokids-a-pioneering-approach-to-elevating-childhood-health-and-development
Care to elaborate?
you dont really beleive all that bunk do you?
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates:
M2Bio Sciences proudly announces the launch of its groundbreaking new division, M2BioKids, a pioneering initiative dedicated to enhancing mental and physical health in the formative years of life, from newborns to children aged five years. Rooted in the cutting-edge intersection of biotechnology and pediatric health science, M2BioKids is set to revolutionize early childhood development through a comprehensive approach encompassing food, nutrition, physical and mental exercises, and critical thinking via AI-driven apps.
The foundational years of a child's life are crucial for setting the stage for lifelong health, well-being, and cognitive abilities. Recognizing the immense potential for positive impact during this pivotal period, M2BioKids leverages the latest scientific research to develop innovative solutions and strategies to optimize growth, health, and developmental outcomes.
Nutritional Science: At the core of M2BioKids' mission is a deep commitment to advancing nutritional science for young children.
Understanding that proper nutrition is the cornerstone of healthy development, our research focuses on identifying optimal dietary patterns and micronutrient intakes that support brain development, immune system strength, and physical growth. Through the creation of scientifically formulated foods and supplements, M2BioKids aims to address common nutritional deficiencies and promote a foundation of health from the earliest stages of life.
Physical Development: Physical activity is another crucial pillar of M2BioKids' holistic approach. Recognizing the critical role of physical development in early childhood, our programs are designed to encourage age-appropriate motor skills through playful, engaging exercises that promote strength, coordination, and overall physical health. By integrating these activities into daily routines, M2BioKids supports the natural growth process while laying the groundwork for an active, healthy lifestyle.
Mental and Cognitive Enhancement: M2BioKids is equally focused on the mental and cognitive aspects of early childhood development. We aim to stimulate critical thinking, problem-solving, and creativity by developing innovative educational tools and programs. Our approach is rooted in the latest cognitive science, ensuring our methods engage young minds and support neural development, language acquisition, and emotional intelligence.
Research and Development: At the heart of M2BioKids is a robust research and development program committed to pushing the boundaries of what's possible in early childhood health and development. Our multidisciplinary team of scientists, pediatric health experts, and educators collaborate to explore new theories, conduct clinical trials, and translate discoveries into practical applications. This relentless pursuit of knowledge ensures that M2BioKids remains at the forefront of scientific advancement, delivering evidence-based solutions that make a real difference in the lives of children and their families.
Interactive AI-Driven App: M2BioKids is developing an interactive AI-driven app to enhance its impact further. This digital platform will engage children in learning activities while offering parents and caregivers valuable nutrition, physical activity, and cognitive development resources. The app will feature gamified learning experiences, interactive storytime, and movement challenges, making learning fun and educational. Personalized recommendations and developmental milestone tracking will provide a tailored experience that evolves with the child.
Market Need and Innovation: The launch of M2BioKids comes in response to a critical and underserved need in the early childhood development sector. Statistics underscore the global challenge of undernutrition, which is a contributing factor in nearly half of all deaths in children under five, highlighting the urgent need for improved nutritional science and interventions. Additionally, with over 130 million babies born each year worldwide, the demand for holistic, scientifically-backed developmental aids is increasing. M2BioKids addresses these needs by offering innovative solutions that promise to significantly impact the health and development of young children, presenting a compelling and sustainable business segment with extensive growth potential.
Future Directions: As M2BioKids grows and evolves, our vision extends beyond the immediate horizon. We are committed to expanding our research to cover a broader spectrum of childhood development issues, exploring innovative therapies, and developing new technologies that address the complex needs of growing children. With a foundation built on science, compassion, and innovation, M2BioKids is poised to lead a new era in childhood development, impacting future generations.
Jeff Robinson, CEO of M2Bio Sciences, stated: "M2BioKids is a groundbreaking initiative that epitomizes M2Bio Sciences' dedication to harnessing the power of AI, biotechnological innovations, and scientific research to enhance children's mental and physical health. By strategically focusing on the critical developmental windows from preconception through the early years, M2BioKids integrates advanced nutritional science, neurodevelopmental strategies, and pioneering digital tools to establish a robust foundation for lifelong health, cognitive well-being, and intellectual prowess. This approach not only aims to cultivate a generation that is healthier, more intellectually capable, and more adaptable to challenges but also sets a new benchmark in pediatric health science, promising a brighter, more resilient future for children globally."
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."
Publicly traded Company (OTC Pink:MRES)
CONTACT:
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Selling pressure??? There was 500k shares traded. And I personally bought 200,000 of them. That’s a no one is buying and no one is selling. It’s a few thousand dollars you banana
Once again, a day of selling pressure when a pr comes out.
REMEMBER THE WUHN
MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward ------ Thursday, 22 February 2024 09:15 AM
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edgemental health therapeutic research driven by artificial intelligence (AI), is pleased to sharethe following M2Enviro updates:
M2Enviro, at the forefront of biotechnological innovation and sustainability, is pioneering mycelium technology to engineer groundbreaking, eco-friendly products. This division is dedicated to redefining the landscape of material science, offering sustainable alternatives to the traditional, environmentally detrimental, petroleum-based materials that dominate our world. In 2023, we achieved remarkable breakthroughs in research and development, culminating in the creation of our flagship innovation, Hempcelium™. This avant-garde biodegradable packaging solution, ingeniously combining hemp with mycelium, stands at the vanguard of environmental stewardship. Hempcelium™ has captured the industry's imagination and positioned itself as a formidable challenger to conventional petroleum-based packaging, heralding a new era of sustainable material science.
As M2Enviro propels into the forthcoming year, the guiding principle is exponential growth-reflecting the boundless expansion characteristic of mycelium networks. The company is poised to dramatically extend its influence and augment its operational capabilities, leveraging the substantial foundation laid in the previous year. This strategic expansion is not merely an increase in scale but a profound amplification of our scientific endeavors, underscoring our commitment to redefining the frontiers of biotechnological innovation and sustainability.
In 2024, M2Enviro embarks on an ambitious continuation of its mission, with a reinforced commitment to research & development and the engineering of novel products, with a particular focus on the advancement of Hempcelium™. This commitment to ongoing scientific inquiry guarantees perpetual innovation, upholding the most stringent standards of excellence. As we transitioned out of 2023, Hempcelium™ was subjected to exhaustive performance evaluations, where it exceeded both our internal criteria and established industry benchmarks across multiple measures of strength-affirming our scientific assertions regarding the material's exceptional resilience, durability, and superior quality. This achievement signifies a milestone in material science and reinforces our position at the forefront of sustainable engineering solutions.
This triumph marks a pivotal moment for the industry, heralding a monumental stride towards providing eco-conscious alternatives without sacrificing performance. The outcomes of our rigorous R&D endeavors over the past two years underscore our unwavering dedication to revolutionizing the industry and affirm the viability of Hempcelium™ as a transformative, sustainable packaging solution. This is not merely progress; it is a bold declaration of our capacity to redefine the future of environmental sustainability.
"In 2023, we achieved a significant milestone in developing the inaugural mycelium composite surfboard, with the official release scheduled for March 2024. M2Enviro is accelerating the fabrication of the next three boards, targeting completion by May 2024. Additionally, we are offering six unique, limited-edition boards on M2Bio Science's OpenSea platform as NFTs, showcasing the innovative potential of this project. This initiative goes beyond traditional surfboard manufacturing; it represents a pioneering step in utilizing mycelium technology, setting new standards for sustainable design and engineering in the surf industry," articulated Stephanus Louwskieter, lead R&D Engineer.
M2Enviro is actively engaging with potential clients behind the scenes, with plans to onboard some in 2024. Due to an overwhelming demand for our Hempcelium™ that far exceeds our current production capabilities, we are taking significant steps to address this exciting challenge. An in-house production facility in Hout Bay is under construction, aimed explicitly at scaling production and operations for increased efficiency and product availability. This strategic expansion is critical for meeting the surging interest and ensuring we can fulfill the growing needs of our market. Additionally, the division will launch targeted social media campaigns to raise awareness and showcase the unique features of Hempcelium™. We are also exploring collaborations with local artists to introduce mycelium composite materials through art and culture, further enhancing public awareness and understanding of the material. These initiatives are designed to meet the current demand and solidify our position as leaders in mycelium composite materials' innovation and sustainable use.
Aidan Price, the visionary MD of M2Enviro, exuded unparalleled enthusiasm for the future, proclaiming, "2023 was the year we laid down our roots, setting the stage for what's to come. As we step into 2024, we're not just ready to grow-we're set to redefine the sustainability landscape. Our relentless pursuit of innovative mycelium applications and unwavering dedication to eco-conscious principles place us at the forefront of the movement towards a greener tomorrow."
With an ambitious eye on exponential growth, M2Enviro is passionately committed to transcending the frontiers of sustainable technology, catering to the sophisticated needs of the environmentally aware consumer.
Never disturb a sleeping bear lol
Great update here today from Warren, who is checking in on in-store placement/merchandising and sales at SPAR stores. Looking pretty good I'd say...@livianaoliveoil @Medspresso @M2Biome $MRES $RLAB pic.twitter.com/SnkPw2s8Vo
— M2Bio Sciences (@m2bio) February 1, 2024
crypto nfts mma AI cannabis mushrooms he missed EV THIS SMELLS BAD
Spin offs is my understanding.
RLAB being the first one. Just waiting to hear on how it's all structured.
But, multiple divisions will be spun off and MRES sh will get a % of all of them ....again, my understanding.
MRES
Has he ever said we'd get spin-off shares or will MRES just become a dividend paying stock? I'm good either way.
I believe so.
Maybe more.
But 2 would be a great start imo.
Be nice when we finally start moving out of this range too. To a higher one of course lol
MRES
Maybe 2 spinoffs this year?? 👍️
kt
F it. Sold off another position and added 200k more. Looking for another 200k today and then I’m done done. I think
Great summary of 2023 and 2024 objectives.
ICE
Followers
|
124
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9564
|
Created
|
04/20/07
|
Type
|
Free
|
Moderators jdcpa1 Iceman GREGG THE GREEK |
Unit 1 Masons Press Building
7 Ravenscraig Road
Woodstock, Cape Town 7925
South Africa
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |